Wichtigstes Mittel für die Diagnose eines Morbus Crohn und die Beurteilung der entzündlichen Aktivität ist die Endoskopie mit histologischer Begutachtung. Da diese Methode aufwändig und oft problematisch ist, wurden in den letzten Jahren zunehmend nicht-invasive Methoden (fort)entwickelt. Hierbei spielen Biomarker eine bedeutende Rolle.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Odze RD. A contemporary and critical appraisal of “indeterminate colitis.” Mod Pathol. 2015;28:S30–46
Reumaux D, Sendid B, Poulain D et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19–35
Vernier G, Sendid B, Poulain D, Colombel J-F. Relevance of Serologic Studies in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2004;6:482–7
Mitsuyama K. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22:1304
Joossens S, Reinisch W, Vermeire S et al. The value of serologic markers in indeterminate colitis: A prospective follow-up study. Gastroenterology. 2002;122:1242–7
Kaul A, Hutfless S, Liu L et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: A systematic review and meta-analysis: Inflamm Bowel Dis. 2012;18:1872–84
Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res. 2013;56:131–42
Vermeire S. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–31
Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–9
Mosli MH, Zou G, Garg SK et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–19
Harries AD, Fitzsimons E, Fifield R et al. Platelet count: a simple measure of activity in Crohn’s disease. Br Med J (Clin Res Ed). 1983;286:1476
Nakarai A, Kato J, Hiraoka S et al. Slight Increases in the Disease Activity Index and Platelet Count Imply the Presence of Active Intestinal Lesions in C-reactive Protein-negative Crohn’s Disease Patients. Intern Med. 2014;53:1905–11
Basso D, Zambon C-F, Plebani M. Inflammatory bowel diseases: from pathogenesis to laboratory testing. Clin Chem Lab Med. 2014;52:471–81
Lin J-F, Chen J-M, Zuo J-H et al. Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity. Inflamm Bowel Dis. 2014;20:1407–15
Fiorino G, Bonifascio C, Malesci A et al. MRI in Crohn’s disease—current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2011;9:23–31
Dong J, Wang H, Zhao J et al. Ultrasound as a diagnostic tool in detecting active Crohn’s disease: a meta-analysis of prospective studies. Eur Radiol. 2014;24:26–33
Gecse K, Brandse S, van Wilpe S et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease. Scand J Gastroenterol. 2015;50:841–7
Menees SB, Powell C, Kurlander J et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–54
Thia KT-J, Chan ES-Y, Ling K-L et al. Role of Procalcitonin in Infectious Gastroenteritis and Inflammatory Bowel Disease. Dig Dis Sci. 2008;53:2960–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vetter, M., Neurath, M.F. & Atreya, R. Biomarker verbessern Versorgung des M. Crohn. MMW - Fortschritte der Medizin 159, 63–68 (2017). https://doi.org/10.1007/s15006-017-9279-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-017-9279-0